By Chris Wack

AstraZeneca said a Phase III trial showed its Imfinzi durvalumab plus Imjudo demonstrated a sustained, clinically meaningful overall survival benefit at four years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.

The pharmaceutical company said that at four years of follow-up, the data show that a single priming dose of Imjudo added to Imfinzi reduced the risk of death by 22% compared with sorafenib.

An estimated 25.2% of patients treated were alive at four years versus 15.1% for those treated with sorafenib.

The safety profile of the Imjudo/Imfinzi regimen was consistent with the known profiles of each medicine, and no new safety signals were observed with longer follow-up. Serious treatment-related adverse events, defined as Grade 3 or 4 and including death, were experienced by 17.5% of patients treated with the regimen versus 9.6% of patients treated with sorafenib.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 29, 2023 10:00 ET (14:00 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more AstraZeneca Charts.